Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects (CLINDE)
Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With Parkinson Disease or Alzheimer Disease and in Healthy Subjects
Sponsor: Institute for Neurodegenerative Disorders
Terminated
Results did not show reason to continue with study.
Other terminated trials from Institute for Neurodegenerative Disorders
- Alzheimer's Disease · Phase PHASE1 · Dec 2010
- Alzheimer Disease · Phase EARLY_PHASE1 · Sep 2010
- Alzheimer Disease · Phase PHASE1 · Sep 2010
- Parkinson Disease · Phase PHASE1 · Oct 2009
- Alzheimer's Disease · Phase PHASE1 · Mar 2009
See all terminations from Institute for Neurodegenerative Disorders
Other Alzheimer Disease trials with similar outcome
Listed as NCT00612872, this PHASE1 trial focuses on Alzheimer Disease and Healthy Controls and remains terminated or withdrawn. Sponsored by Institute for Neurodegenerative Disorders, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
May 2019 — Jan 2021 [monthly]
Terminated PHASE1
-
Jun 2018 — May 2019 [monthly]
Terminated PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institute for Neurodegenerative Disorders
For direct contact, visit the study record on ClinicalTrials.gov .